معرفی
Anika Nagelkerke serves as an Associate Professor at the University of Groningen, holding dual appointments in the Faculty of Science and Engineering and the Faculty of Medical Sciences (UMCG). Her work in the Pharmaceutical Analysis group bridges cancer biology and respiratory medicine, with office location at the University Medical Center Groningen (A Deusinglaan 1).
Her research spans malignant neoplasms, breast cancer, and molecular pathways including membrane proteins, unfolded protein response, and autophagy. She simultaneously investigates COPD pathogenesis and develops regenerative therapies for alveolar repair through pharmaceutical innovation and molecular signaling studies.
Recent publications reveal a strong translational focus on respiratory regenerative medicine, featuring osteoglycin-based epithelial repair mechanisms, enzymatically degradable scaffolds, and bronchial inflammation modulation. Her work integrates pharmaceutical technology with cell biology to address critical gaps in COPD treatment.
Dr. Nagelkerke's contributions have been recognized with significant awards:
- Developing a novel regenerative therapy for effective COPD treatment based on the secretome of mesenchymal stem cells (2022)
- Developing a novel extracellular vesicles-based regenerative therapy for COPD (2021)
She actively leads collaborative research initiatives through editorial roles in Frontiers in Oncology and leadership positions in Human Organ and Disease Model Technologies, while hosting international researchers and engaging in professional outreach through the Dutch Society of Toxicology.
Her laboratory work operates at the intersection of the Groningen Research Institute of Pharmacy (GRIP) and UMCG, utilizing precision-cut lung slices, pulmonary organoid models, and pharmaceutical formulation techniques to advance regenerative respiratory therapeutics.
